These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 24832115)
1. The medicinal chemistry of liver X receptor (LXR) modulators. Tice CM; Noto PB; Fan KY; Zhuang L; Lala DS; Singh SB J Med Chem; 2014 Sep; 57(17):7182-205. PubMed ID: 24832115 [TBL] [Abstract][Full Text] [Related]
2. The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease. Fessler MB Pharmacol Ther; 2018 Jan; 181():1-12. PubMed ID: 28720427 [TBL] [Abstract][Full Text] [Related]
3. Recent progress in liver X receptor-selective modulators. Ratni H; Wright MB Curr Opin Drug Discov Devel; 2010 Jul; 13(4):403-13. PubMed ID: 20597026 [TBL] [Abstract][Full Text] [Related]
4. LXR as a novel antithrombotic target. Spyridon M; Moraes LA; Jones CI; Sage T; Sasikumar P; Bucci G; Gibbins JM Blood; 2011 May; 117(21):5751-61. PubMed ID: 21411760 [TBL] [Abstract][Full Text] [Related]
5. Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. Zhang Y; Breevoort SR; Angdisen J; Fu M; Schmidt DR; Holmstrom SR; Kliewer SA; Mangelsdorf DJ; Schulman IG J Clin Invest; 2012 May; 122(5):1688-99. PubMed ID: 22484817 [TBL] [Abstract][Full Text] [Related]
6. [Advances in the study of anti-atherosclerosis drugs]. Guo CB; Li S Yao Xue Xue Bao; 2007 Mar; 42(3):231-5. PubMed ID: 17520819 [TBL] [Abstract][Full Text] [Related]
7. Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis. Zhang XQ; Even-Or O; Xu X; van Rosmalen M; Lim L; Gadde S; Farokhzad OC; Fisher EA Adv Healthc Mater; 2015 Jan; 4(2):228-36. PubMed ID: 25156796 [TBL] [Abstract][Full Text] [Related]
8. X-ray structures of the LXRalpha LBD in its homodimeric form and implications for heterodimer signaling. Fradera X; Vu D; Nimz O; Skene R; Hosfield D; Wynands R; Cooke AJ; Haunsø A; King A; Bennett DJ; McGuire R; Uitdehaag JC J Mol Biol; 2010 May; 399(1):120-32. PubMed ID: 20382159 [TBL] [Abstract][Full Text] [Related]
9. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells. Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and pharmacology of 1,1-bistrifluoromethylcarbinol derivatives as liver X receptor β-selective agonists. Koura M; Matsuda T; Okuda A; Watanabe Y; Yamaguchi Y; Kurobuchi S; Matsumoto Y; Shibuya K Bioorg Med Chem Lett; 2015 Jul; 25(13):2668-74. PubMed ID: 25998501 [TBL] [Abstract][Full Text] [Related]
11. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits. Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689 [TBL] [Abstract][Full Text] [Related]
12. Liver X receptors as potential therapeutic targets in atherosclerosis. Zhu Y; Li Y Clin Invest Med; 2009 Oct; 32(5):E383-94. PubMed ID: 19796580 [TBL] [Abstract][Full Text] [Related]
13. Targeting liver X receptors in human health: deadlock or promising trail? Viennois E; Pommier AJ; Mouzat K; Oumeddour A; El Hajjaji FZ; Dufour J; Caira F; Volle DH; Baron S; Lobaccaro JM Expert Opin Ther Targets; 2011 Feb; 15(2):219-32. PubMed ID: 21204733 [TBL] [Abstract][Full Text] [Related]
14. Liver X receptors inhibit macrophage proliferation through downregulation of cyclins D1 and B1 and cyclin-dependent kinases 2 and 4. Pascual-García M; Carbó JM; León T; Matalonga J; Out R; Van Berkel T; Sarrias MR; Lozano F; Celada A; Valledor AF J Immunol; 2011 Apr; 186(8):4656-67. PubMed ID: 21398609 [TBL] [Abstract][Full Text] [Related]
15. Liver X receptors (LXR) as therapeutic targets in dyslipidemia. Bełtowski J Cardiovasc Ther; 2008; 26(4):297-316. PubMed ID: 19035881 [TBL] [Abstract][Full Text] [Related]
16. Selective partial agonism of liver X receptor alpha is related to differential corepressor recruitment. Phelan CA; Weaver JM; Steger DJ; Joshi S; Maslany JT; Collins JL; Zuercher WJ; Willson TM; Walker M; Jaye M; Lazar MA Mol Endocrinol; 2008 Oct; 22(10):2241-9. PubMed ID: 18669643 [TBL] [Abstract][Full Text] [Related]
17. Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Blaschke F; Leppanen O; Takata Y; Caglayan E; Liu J; Fishbein MC; Kappert K; Nakayama KI; Collins AR; Fleck E; Hsueh WA; Law RE; Bruemmer D Circ Res; 2004 Dec; 95(12):e110-23. PubMed ID: 15539633 [TBL] [Abstract][Full Text] [Related]
18. CCAAT/enhancer binding protein β deletion increases mitochondrial function and protects mice from LXR-induced hepatic steatosis. Rahman SM; Choudhury M; Janssen RC; Baquero KC; Miyazaki M; Friedman JE Biochem Biophys Res Commun; 2013 Jan; 430(1):336-9. PubMed ID: 23159614 [TBL] [Abstract][Full Text] [Related]
19. LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms. Morello F; Saglio E; Noghero A; Schiavone D; Williams TA; Verhovez A; Bussolino F; Veglio F; Mulatero P Atherosclerosis; 2009 Nov; 207(1):38-44. PubMed ID: 19426978 [TBL] [Abstract][Full Text] [Related]
20. Combination of virtual screening and high throughput gene profiling for identification of novel liver X receptor modulators. Cheng JF; Zapf J; Takedomi K; Fukushima C; Ogiku T; Zhang SH; Yang G; Sakurai N; Barbosa M; Jack R; Xu K J Med Chem; 2008 Apr; 51(7):2057-61. PubMed ID: 18324758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]